Sign In
Buy CNTB
$2.02
-0.0700 (-3.35%)
At Close: Jul 31, 2026
Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Conference
05:04am, Monday, 02'nd Mar 2026
Connect Biopharma (NASDAQ: CNTB) CEO Barry Quart told investors at Oppenheimer's 36th Annual Healthcare Life Science Conference that the company is advancing its lead asset, rademikibart, into what it
BML Capital Management LLC Sells 554,058 Shares of Connect Biopharma Holdings Limited Sponsored ADR $CNTB
04:22am, Monday, 23'rd Feb 2026
BML Capital Management LLC cut its stake in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB) by 30.4% during the third quarter, according to its most recent 13F filing with the Securiti
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
09:00am, Thursday, 19'th Feb 2026
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical compan
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of “Moderate Buy” by Analysts
03:26am, Saturday, 14'th Feb 2026
Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are currentl
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Receives Average Rating of “Moderate Buy” from Brokerages
06:13am, Tuesday, 20'th Jan 2026
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five brokerages that are currently covering the com
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
08:00am, Monday, 12'th Jan 2026
– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
09:00am, Monday, 24'th Nov 2025
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical compan
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
09:00am, Wednesday, 12'th Nov 2025
– Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 – – New Drug Application for rademiki
Connect Biopharma Holdings Limited ( CNTB ) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST Company Participan
Analyzing Connect Biopharma (CNTB) & Its Rivals
03:19am, Friday, 31'st Oct 2025
Connect Biopharma (NASDAQ: CNTB - Get Free Report) is one of 618 publicly-traded companies in the "MED - BIOMED/GENE" industry, but how does it compare to its peers? We will compare Connect Biopharma
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
09:00am, Monday, 29'th Sep 2025
– Rademikibart demonstrated rapid and significant improvement in lung function and asthma control in patients, with greatest improvements observed in those with elevated baseline levels of key type
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
08:00am, Thursday, 04'th Sep 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on trans
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
08:00am, Wednesday, 03'rd Sep 2025
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on tr
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
09:00am, Wednesday, 27'th Aug 2025
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transf
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
08:00am, Thursday, 14'th Aug 2025
Company and Former Cincinnati Bengals Running Back Known for the “Ickey Shuffle” Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug
